Excited and grateful that we received $500K from an angel investor, enabling us to move forward with our CLIA LDT certification and prototype testing for CAL, a first-in-class precision cancer diagnostic instrument.
- cmargain
top of page
EMPIRI INC.
Search
Recent Posts
See AllEMPIRI's E-slice 3D tumor culture platform for real-time evaluation of therapeutic candidates can now be accessed through our store-front at Scienist.Com for expedited study quoting and contracting.
Funding to support a cancer diagnostic system to measure empirical treatment response Houston, TX, July 20, 2023 - EMPIRI, Inc., who is revolutionizing how we treat cancer by providing empirical, pers
San Francisco, CA, Jan 8, 2023– EMPIRI today announced that it is presenting at Biotech Showcase™ 2023. This year, registered attendees can view EMPIRI’s presentation live, and also access a recorded
bottom of page